Long term bank facilities (Rs 527.75 crore) - CARE BBB-; Stable
Short term bank facilities (Rs 171.20 crore) - CARE A3
Non convertible debentures (Rs 200 crore) - CARE BBB-; Stable
Non convertible debentures (Rs 50 crore) - CARE BBB-; Stable
The ratings were given, inter alia, after factoring in the tie-up with various global partners for supply of vaccines and respiratory antibiotic, diversified product portfolio spread across multiple therapeutic segments, accredited manufacturing facilities along with R&D-focused approach, established marketing network with global presence, improvement in total operating income and operating profit margins in FY22 and successful raising of funds through rights issue and NCD issue.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
